11/5/2026

speaker
Carly
Conference Call Operator

Good afternoon. My name is Carly, and I will be your conference call operator today. I would like to welcome everyone to Solventum's third quarter 2026 earnings call. As a reminder, this conference is being recorded. All lines have been placed on mute to prevent any background noise. I would now like to turn the program over to your host for today's conference, Amy Wakeham, Senior Vice President of Inventor Relations and Finance Communications. Please proceed.

speaker
Amy Wakeham
Senior Vice President, Investor Relations and Finance Communications

Thank you. Good afternoon and welcome to Solventum's third quarter fiscal year 2026 earnings call. Joining me on today's call are Chief Executive Officer Bryan Hanson and Chief Financial Officer Wayde McMillan. A replay of today's earnings call will be available later today on the investor relations section of our corporate website. The earnings press release and the presentation are both available there now. During today's call, Our discussion and any comments we make will be on a non-GAAP basis unless they are specifically called out as GAAP. The non-GAAP information discussed is not intended to be considered in isolation or as a substitute for the reported GAAP financial information. Please review the supporting schedules in today's earnings press release to reconcile the non-GAAP measures with the GAAP reported numbers. Our discussion on today's call will include forward-looking statements including but not limited to expectations about our future financial and operating performance. These statements are made based on reasonable assumptions. However, our actual results could differ. Please review our SEC filings for a complete discussion of the risk factors that could cause our actual results to differ materially from any forward-looking statements made today. Following our prepared remarks, we'll hold a question and answer session. For the Q&A portion of today's call, I'd like to remind our analysts to please limit yourself to one question. If you have additional questions, you can rejoin the Q&A queue. I'd like to now hand the call over to Bryan.

speaker
Bryan Hanson
Chief Executive Officer

All right. Thanks, Amy, and thanks to everyone for joining us today. And let me just start by saying that in the third quarter, we executed the largest and most complex ERP cutover in the history of this company. And thankfully, it was also the last on our path to full separation. and I can tell you from experience that a cutover at that scale is never seamless and ours was no exception. But the mitigation plan that we built, it held and this team delivered through it. And to our customers, I want to say thank you for your partnership. You leaned in and worked with our teams and that's what kept product moving to the patients who needed them. And to our team specifically, this was a significant cross-functional effort. We had supply chain, IT, commercial, Customer service, quality, finance, all pulling in the same direction. And that kind of team dynamic under that kind of team pressure isn't something you can just install. You either have it or you don't. We clearly have it. And speaking of having it, let's get into the quarter. All key financial metrics were in line or ahead of our expectations with organic growth and EPS both above plans. and as we communicated in August, these results reflect the advanced orders reversing back out of the quarter following the ERP cutover. And once again, this team has proven that the say-do equation that we value so much is alive and well regardless of the challenges around us. And as solid as the quarter was, the progress on our transformation has to be just as encouraged. You know, just a quick reminder, we're running a three-phase transformation, stabilize and separate the business, Reposition for profitable growth and optimize the portfolio. And as always, those phases are not sequential. They're running concurrently. So let me start with separation because there's a pretty big headline here. You know, with the Americas cut over behind us, separation is now more than 90% complete. Now, we still have work to do to close out the rest, but the key message here, the important message is that the structural work, the risky work, that's done. This will also significantly strengthen our free cash flow as separation costs roll off which will be reflected in our Q4 performance. I can just say this is a significant milestone for Solventum and I'm extremely proud of the team for getting us here. And related to that, and this is also important, we successfully renegotiated our raw materials supply agreement with 3M, aligning on a long-term supply agreement that is better for both companies. And there are two things I want you to take away from this for Solventum. First, it strengthens supply continuity for the critical materials that leverage our intellectual property. And second, it's an important variable and our ability to improve year over year margins in 2027, particularly given the known tariff headwinds created by the one-time tariff refund we received in 2026. And it clearly increases confidence in our whole code 2028 LRP target of 23 to 25%. Now moving on to portfolio optimization and specifically HIS with a focus on continuing to execute our portfolio optimization strategy. In August, we announced our intent to separate our health information systems business. And as I said last quarter, our focus here is clear. We're going to run the most shareholder friendly separation process that we can, where both businesses have enhanced strategic clarity and more focused investment. And as a result, we're looking at both spin and sale options and taking the appropriate actions to move both of those options forward. When it comes to proceeds from the separation path chosen, we have two primary areas of focus. The first is paying down debt to hold our credit rating, and the second is returning capital to shareholders. And when it comes to Remainco, we will have a very focused and compelling business. Remember that four of our five growth drivers, as well as the Acera acquisition, will remain with Solventum. And on a smaller base, their impact will be magnified, as will future tuck-in acquisitions. And the largest majority of our go-forward margin expansion levers, well, they sit inside of the Remainco business. So our margin improvement opportunity off a new starting point will be even more compelling. but as I've said before, portfolio moves are only part of the story. The engine here is organic growth and our growth driver areas continue to fuel the growth that we design them to. As a quick reminder, there are five growth drivers, negative pressure wound therapy, IV site management, sterilization assurance, core restoratives, and revenue cycle management. Together, they represent a multi-billion dollar opportunity. And for much of this opportunity, we're not trying to break into new accounts and displace an incumbent, we're simply going to customers who already trust us in showing them with data a better standard of care that they're not using yet. That's fundamentally a lower risk path to growth, and it's a big part of why we have the conviction we do on the long-range plan. And let me just make it real with one example. This quarter, I'll talk about our VAC system, which is our proprietary negative pressure wound therapy technology. And I'll look at the U.S. In the U.S. alone, complex and chronic wounds affect roughly one in six Medicare beneficiaries. One in six Medicare beneficiaries. and depending on whose study you read, that's about 10.5 million people at a cost to Medicare north of 20 billion per year. Those are big numbers. And as we know, big numbers tend to go in one ear and out the other. So let me describe it this way. For a patient with a diabetic foot ulcer, five-year mortality runs somewhere between 30 and 55%. Once a patient progresses to major amputation, more than half will not survive the next five years. Studies with VAC therapy show wounds are ready for closure almost twice as fast. Studies also show a 60% reduction in amputations versus non-VAC treatments. And yet VAC therapy is only used about 10% of the time. So roughly 90% of this opportunity is still in front of us. And it's not sitting behind a technology gap. It's not sitting behind an evidence gap. The studies are clear, the therapy works. One of the major reasons it doesn't get used more often is just friction. It's the workflow complexity in the time of application on a busy short staff unit. That's why we've launched the VAC peel-in-place dressing to engineer the complexity in the time out of the application. Peel-in-place shows a 61% reduction in application time and it can stay on for up to seven days versus currently being changed every two to three days, significantly reducing time and complexity. But our innovation did not just enhance the clinical workflow, the design improves the patient experience with 10 out of 10 patients reporting no pain upon removal. And I can tell you for busy care teams and their patients, simpler application, fewer dressing changes, and less pain for removal make an established therapy easier to incorporate into everyday care. So think about this. Same customer, same call point, therapy we already have with outcome studies already in hand for patients who already qualify for it, but nine times out of ten not getting it, and we intend to close that gap. Of course, attractive markets aren't enough. You also need to ensure cross-functional focus, particularly across your R&D engine, commercial, and market development infrastructure. And that's exactly what our growth driver strategy accomplishes. In Med-Surg, three of our five growth drivers live here. All three continue to contribute. In the area that I just talked about, negative pressure wound therapy, our vacuum-in-place dressing continues to ramp, and Provena keeps building on the single-use side of the equation. In IV site management, we continue to gain traction behind Tegaderm CHG and our Kuros caps, which really creates our belt and suspenders approach to reducing catheter-related bloodstream infections. And on sterilization assurance, we're now fully in market with the three new Attest products we launched earlier this year. On Acera, the integration continues to be on track and the business delivered its best quarter on record. We also received a 510K clearance for the combined use of Restrada with the VAC therapy faster than we expected. and it's the first of its kind. The commercial benefit here is every bit as important as a clinical one. It lets us now co-market the technologies and put our combined commercial organizations behind them. That's exactly the leverage we underwrote when we acquired Acera. In dental, core restoratives and new product launches are doing the heavy lifting. with ClinProClear, the Filtek EasyMatch family of launches, our composite warmer, and Clarity aligner attachments continuing to gain traction. We also move forward with the limited launch phase of our Clarity composite veneers, which is obviously focused on the aesthetic space. With early market access delivering 1,000 plus transformed smiles, giving us strong validation ahead of the full launch expected in the first part of 2027. and in HIS, our revenue cycle management continues to perform with 360 and Compass adoption expanding, our AI-driven autonomous coding applications gaining traction and continued international expansion. This business is running hard and I can say that this team has stayed completely focused through the separation announcement and I can't tell you how much I appreciate that. Stepping back on innovation, beyond the products I've already discussed, we still have a strong pipeline of new products across each of our businesses, and many of those will be discussed during our upcoming Investor Day in March of next year. The key message, I think, is pretty simple. We see significant opportunity for growth by leveraging our newly optimized sales channel to drive three key areas. First, the underpenetration of clinically differentiated brands like the VAC system that are already in the market. Two is newly launched innovation and our pending new product pipeline, and three is acquired innovation like Restrada. Okay, I've thrown a lot at you, so let me just leave you with a few key takeaways. First, we executed the largest ERP cutover in the history of this company and still delivered on revenue, margin, and free cash flow. Even in the most operationally complex quarter, the Seydoux equation continues. Second, the separation for 3M is 90 plus percent behind us. That retires the execution risk of a major separation and it significantly strengthens our free cash flow. Third, our growth driver areas create a multi-billion dollar roadmap for revenue and margin growth, with much of this in customers we already serve. And then fourth, RemainCo will not only be a more strategically aligned and focused business, we will also have a compelling and enhanced growth and margin acceleration opportunity. Said simply, we are a more focused, more disciplined company with our separation nearly complete, our portfolio optimization in full swing, margin and free cash flow structure stronger, and growth engine running. and with that, I'm gonna turn it over to Wayde. Okay, Wayde, take it from here.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Investor presentation